Tapering, Cruising, and Coming Off

There are three broad strategies for managing the transition off a cycle: a PCT-based recovery, a cruise (TRT-dose bridge), or a taper. Each has different pharmacokinetic and physiological consequences.

1. PCT (full recovery)

Stop all compounds, wait for clearance (≈5 × half-life), then run a SERM-based PCT to restart the HPG axis. See our PCT Planner for clearance estimates.

2. Cruise / TRT bridge

Drop to a TRT-dose of testosterone (e.g., 100–150 mg/week) rather than fully coming off. This avoids the crash but does not restore the HPG axis — endogenous production stays suppressed. A cruise is effectively ongoing TRT with the same long-term monitoring needs.

3. Taper

Gradually reduce dose to ease the transition. Pharmacokinetically, tapering a long ester has limited effect because clearance is governed by half-life, not dose — but it can reduce psychological shock.

Choosing a strategy

The right path depends on goals, age, baseline hormone status, and willingness to commit to lifelong TRT. There is no universally correct answer — only informed trade-offs made with bloodwork and clinical guidance.